Our 7th Annual Open Meeting took place at the Royal College of Physicians, London on March 10, 2020.
We would like to thank all of our speakers, exhibitors, delegates and sponsors for making #UKPGx2020 such a success!
Recorded talks are being processed and edited, these will be available shortly.
Welcome : Professor Sir Munir Pirmohamed
Precision Public Health : Professor Sir John Bell
Chromosomal instability and genome plasticity in cancer evolution, immune evasion and metastasis : Professor Charles Swanton
The NHS Genomic Medicine Service : Professor Dame Sue Hill
Session 2: Early Career Researchers
Polygenic Risk Scoring - An Overview of Theory, Practice and Usefulness for using Genetic Data in Risk Prediction : Dr Jack Euesden
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens : Dr Fiona Behan
Session 3: Nucleic acid based therapies
Somatic and germline genome editing - promises, perils and pipedreams : Professor Robin Lovell-Badge
Antisense oligonucleotide therapy for Huntington's disease : Professor Sarah Tabrizi
Gene therapy in haemophilia : Professor Edward Tuddenham
Session 4: Rare Diseases
Rare Disease Clinical Development - Locked Nucleic Acid therapy for Angelman Syndrome : Dr Michelle Krishnan
Pulmonary arterial hypertensions - molecular stratification of a rare disease : Professor Martin Wilkins
Evolving insights into AAV (adeno-associated virus)-based gene therapies for neuromuscular diseases: Professor Thomas Voit
Close of conference : Professor Sir Munir Pirmohamed
Once again we had some excellent speakers with Sir John Bell and Dame Sue Hill providing keynote addresses.
Charles Swanton highlighted how precision medicine in cancer is moving forward and this year there were sessions on the latest advances in gene based therapies and rare diseases. Early career researchers presented their cutting edge work.
The meeting attracted leading representatives from academia, healthcare and industry sectors, regulators, and patients, so was an ideal opportunity to forge multidisciplinary network partnerships.
All proceeds from the event go to funding our endeavours of promoting the use of personalised medicine in the clinic to provide patients with improved healthcare.